title: The importance of hypoxia-regulated, RPE-targeted gene therapy for choroidal neovascularization.
authors.affiliation: Department of Ophthalmology, John A. Moran Eye Center, University of Utah, Salt Lake City, UT, USA. tyler.smith@hsc.utah.edu
authors.forename: George W
authors.initials: GW
authors.lastname: Smith
authors.forename: C Kathleen
authors.initials: CK
authors.lastname: Dorey
authors.forename: Howard
authors.initials: H
authors.lastname: Prentice
authors.forename: Janet
authors.initials: J
authors.lastname: Blanks
mesh_terms: D020256:Choroidal Neovascularization / Q000235:genetics* / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000235:genetics*; D008268:Macular Degeneration / Q000235:genetics / Q000628:therapy; D055213:Retinal Pigment Epithelium / Q000502:physiology*; D057135:Wet Macular Degeneration / Q000235:genetics / Q000628:therapy
chemical_list: C497442:HIF1A protein, human; D051795:Hypoxia-Inducible Factor 1, alpha Subunit